AU2011214104B2 - Peptides for vaccine against birch allergy - Google Patents

Peptides for vaccine against birch allergy Download PDF

Info

Publication number
AU2011214104B2
AU2011214104B2 AU2011214104A AU2011214104A AU2011214104B2 AU 2011214104 B2 AU2011214104 B2 AU 2011214104B2 AU 2011214104 A AU2011214104 A AU 2011214104A AU 2011214104 A AU2011214104 A AU 2011214104A AU 2011214104 B2 AU2011214104 B2 AU 2011214104B2
Authority
AU
Australia
Prior art keywords
seq
variant
set forth
polypeptide
polypeptide set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011214104A
Other languages
English (en)
Other versions
AU2011214104A1 (en
Inventor
Roderick Peter Hafner
Paul Laidler
Mark Larche
Guy Layton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Niox Healthcare Ltd
Original Assignee
Circassia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Circassia Ltd filed Critical Circassia Ltd
Publication of AU2011214104A1 publication Critical patent/AU2011214104A1/en
Application granted granted Critical
Publication of AU2011214104B2 publication Critical patent/AU2011214104B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A61K39/36—Allergens from pollen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
AU2011214104A 2010-02-15 2011-02-15 Peptides for vaccine against birch allergy Ceased AU2011214104B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1002559.1 2010-02-15
GBGB1002559.1A GB201002559D0 (en) 2010-02-15 2010-02-15 Birch peptides for vaccine
PCT/GB2011/000206 WO2011098778A2 (en) 2010-02-15 2011-02-15 Peptides for vaccines against birch allergy

Publications (2)

Publication Number Publication Date
AU2011214104A1 AU2011214104A1 (en) 2012-09-06
AU2011214104B2 true AU2011214104B2 (en) 2015-05-28

Family

ID=42110757

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011214104A Ceased AU2011214104B2 (en) 2010-02-15 2011-02-15 Peptides for vaccine against birch allergy

Country Status (20)

Country Link
US (2) US9017689B2 (cg-RX-API-DMAC7.html)
EP (2) EP3056213A1 (cg-RX-API-DMAC7.html)
JP (2) JP5926198B2 (cg-RX-API-DMAC7.html)
KR (1) KR20120120965A (cg-RX-API-DMAC7.html)
CN (1) CN102762225B (cg-RX-API-DMAC7.html)
AU (1) AU2011214104B2 (cg-RX-API-DMAC7.html)
CA (2) CA2789353A1 (cg-RX-API-DMAC7.html)
DK (1) DK2536429T3 (cg-RX-API-DMAC7.html)
EA (1) EA201290792A1 (cg-RX-API-DMAC7.html)
ES (1) ES2573651T3 (cg-RX-API-DMAC7.html)
GB (2) GB201002559D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20160481T1 (cg-RX-API-DMAC7.html)
HU (1) HUE029138T2 (cg-RX-API-DMAC7.html)
IL (1) IL221196A0 (cg-RX-API-DMAC7.html)
MX (1) MX2012009431A (cg-RX-API-DMAC7.html)
NZ (1) NZ602380A (cg-RX-API-DMAC7.html)
PL (1) PL2536429T3 (cg-RX-API-DMAC7.html)
SG (1) SG183198A1 (cg-RX-API-DMAC7.html)
SI (1) SI2536429T1 (cg-RX-API-DMAC7.html)
WO (1) WO2011098778A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
WO2013119853A1 (en) * 2012-02-07 2013-08-15 La Jolla Institute For Allergy And Immunology Epitopes from allergen proteins and methods and uses for immune response modulation
GB201209862D0 (en) 2012-06-01 2012-07-18 Circassia Ltd Cladosporium peptides
GB201211586D0 (en) * 2012-06-29 2012-08-15 Circassia Ltd Japanese cedar peptides for preventing or treating allergy
US20150088644A1 (en) 2013-09-23 2015-03-26 Facebook, Inc., a Delaware corporation Predicting User Interactions With Objects Associated With Advertisements On An Online System
CN106699584B (zh) * 2016-12-30 2018-06-26 南京农业大学 一种利用花粉作为天然催化剂制备的γ-氨基丁酸及其制备方法和应用
IL270894B2 (en) 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
CN110175468B (zh) * 2019-05-05 2020-12-01 浙江工业大学 一种保留分布特征的姓名脱敏方法
CN115633666B (zh) * 2021-07-19 2025-11-18 四川大学华西医院 人源化双致敏动物模型和系统性过敏动物模型的构建方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081028A2 (en) * 2003-03-14 2004-09-23 University Of Lausanne Allergen peptide fragments and use thereof
WO2009022154A2 (en) * 2007-08-15 2009-02-19 Circassia Limited Peptide with multiple epitopes

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
WO1994001560A1 (en) 1991-07-12 1994-01-20 Immulogic Pharmaceutical Corporation Allergenic proteins and peptides from japanese cedar pollen
US5968526A (en) 1994-04-14 1999-10-19 Immulogic Pharamaceutical Corporation T cell epitopes of the major allergens from Dermatophagoides (house dust mite)
JP2002500198A (ja) 1998-01-09 2002-01-08 サーカシア リミテッド 脱感作のための方法及び組成物
FR2788698B1 (fr) 1999-01-27 2001-03-30 Commissariat Energie Atomique Peptides et proteines aptes a desensibiliser les sujets allergiques au venin d'abeille et compositions les contenant
WO2003047618A2 (en) 2001-12-05 2003-06-12 Circassia Limited Immunotherapeutic methods and systems
ES2244708T3 (es) 2002-09-27 2005-12-16 Biomay Produktions- Und Handels- Aktiengesellschaft Vacunas hipoalergenicas contra la alergia basadas en el alergeno phl p 7 de polen de cola de zorro.
US20110038881A1 (en) 2007-05-09 2011-02-17 Circassia Limited Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation
GB0710529D0 (en) * 2007-06-01 2007-07-11 Circassia Ltd Vaccine
US8821887B2 (en) 2008-08-15 2014-09-02 Circassia Limited T-cell antigen peptide from allergen for stimulation of IL-10 production
GB201002559D0 (en) * 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004081028A2 (en) * 2003-03-14 2004-09-23 University Of Lausanne Allergen peptide fragments and use thereof
WO2009022154A2 (en) * 2007-08-15 2009-02-19 Circassia Limited Peptide with multiple epitopes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FOCKE et al "Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination.",Clin Exp Allergy 2004; 34(10):1525-1533. *
HUFNAGL et al "Intranasal tolerance induction with polypeptides derived from 3 noncross-reactive major aeroallergens prevents allergic polysensitization in mice", J. Allergy Clin Immunol 2005; 116(2): 370-376. *
VRTALA et al "Induction of blocking antibodies with T cell epitope-containing hypoallergenic recombinant Bet v 1 fragments", Int Arch Allergy Immunol. 2001;124(1-3):107-108. *

Also Published As

Publication number Publication date
CN102762225A (zh) 2012-10-31
SI2536429T1 (sl) 2016-08-31
GB2481475A (en) 2011-12-28
AU2011214104A1 (en) 2012-09-06
EP2536429A2 (en) 2012-12-26
HK1165700A1 (en) 2012-10-12
CN102762225B (zh) 2015-05-13
EA201290792A1 (ru) 2013-03-29
WO2011098778A3 (en) 2011-12-15
CA2789353A1 (en) 2011-08-18
GB201102657D0 (en) 2011-03-30
KR20120120965A (ko) 2012-11-02
HUE029138T2 (hu) 2017-02-28
GB2481475B (en) 2012-09-19
US9017689B2 (en) 2015-04-28
JP5926198B2 (ja) 2016-05-25
US20130243798A1 (en) 2013-09-19
MX2012009431A (es) 2012-09-12
NZ602380A (en) 2014-10-31
SG183198A1 (en) 2012-09-27
EP2536429B1 (en) 2016-02-10
ES2573651T3 (es) 2016-06-09
IL221196A0 (en) 2012-10-31
DK2536429T3 (en) 2016-05-23
WO2011098778A2 (en) 2011-08-18
GB201002559D0 (en) 2010-03-31
HRP20160481T1 (hr) 2016-06-03
US20150196635A1 (en) 2015-07-16
PL2536429T3 (pl) 2016-09-30
WO2011098778A8 (en) 2012-09-27
EP3056213A1 (en) 2016-08-17
CA3139588A1 (en) 2011-08-18
JP2016166194A (ja) 2016-09-15
JP2013519717A (ja) 2013-05-30

Similar Documents

Publication Publication Date Title
US9744222B2 (en) Peptide for vaccine
DK2536429T3 (en) Peptides for vaccines birch allergy
AU2010212193B2 (en) Grass peptides for vaccine
AU2013203568B2 (en) Peptides for desensibilization against allergens
AU2013202362B2 (en) Grass Peptides for Vaccine
HK1164700B (en) Peptides for desensibilization against allergens
HK1132194B (en) Peptides for desensibilization against allergens

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PEPTIDES FOR VACCINE AGAINST BIRCH ALLERGY

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired